Reported Cases of Serotonin Syndrome in MDMA Users in FAERS Database
3,4-Methylenedioxymethamphetamine (MDMA), is investigated as a treatment for post-traumatic stress disorder and other anxiety-related conditions in multiple placebo-controlled and open label studies. MDMA-assisted therapy is projected for approval by the United States Food and Drug Administration (F...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-01-01
|
| Series: | Frontiers in Psychiatry |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fpsyt.2021.824288/full |
| _version_ | 1798027098212794368 |
|---|---|
| author | Tigran Makunts Tigran Makunts Lisa Jerome Ruben Abagyan Alberdina de Boer |
| author_facet | Tigran Makunts Tigran Makunts Lisa Jerome Ruben Abagyan Alberdina de Boer |
| author_sort | Tigran Makunts |
| collection | DOAJ |
| description | 3,4-Methylenedioxymethamphetamine (MDMA), is investigated as a treatment for post-traumatic stress disorder and other anxiety-related conditions in multiple placebo-controlled and open label studies. MDMA-assisted therapy is projected for approval by the United States Food and Drug Administration (FDA) and other regulatory agencies worldwide within the next few years. MDMA is a monoamine releaser and uptake inhibitor affecting serotonin, potentially increasing the risk of serotonin syndrome (SS). No instances of SS have occurred in clinical trials. The relatively small number of patients in controlled trials warranted a survey of FDA Adverse Event Reporting System data for the occurrence of SS in a larger database. We found 20 SS cases in people exposed to MDMA, all of which had also taken one or more substances with serotonergic properties in addition to MDMA, including amphetamines, stimulants, and opioids. There were no cases of SS associated with MDMA where MDMA was the sole reported compound taken. |
| first_indexed | 2024-04-11T18:45:57Z |
| format | Article |
| id | doaj.art-1a874c8ec2a243d7a006fa41ab159435 |
| institution | Directory Open Access Journal |
| issn | 1664-0640 |
| language | English |
| last_indexed | 2024-04-11T18:45:57Z |
| publishDate | 2022-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Psychiatry |
| spelling | doaj.art-1a874c8ec2a243d7a006fa41ab1594352022-12-22T04:08:47ZengFrontiers Media S.A.Frontiers in Psychiatry1664-06402022-01-011210.3389/fpsyt.2021.824288824288Reported Cases of Serotonin Syndrome in MDMA Users in FAERS DatabaseTigran Makunts0Tigran Makunts1Lisa Jerome2Ruben Abagyan3Alberdina de Boer4MAPS Public Benefit Corporation, San Jose, CA, United StatesSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, San Diego, CA, United StatesMAPS Public Benefit Corporation, San Jose, CA, United StatesSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, San Diego, CA, United StatesMAPS Public Benefit Corporation, San Jose, CA, United States3,4-Methylenedioxymethamphetamine (MDMA), is investigated as a treatment for post-traumatic stress disorder and other anxiety-related conditions in multiple placebo-controlled and open label studies. MDMA-assisted therapy is projected for approval by the United States Food and Drug Administration (FDA) and other regulatory agencies worldwide within the next few years. MDMA is a monoamine releaser and uptake inhibitor affecting serotonin, potentially increasing the risk of serotonin syndrome (SS). No instances of SS have occurred in clinical trials. The relatively small number of patients in controlled trials warranted a survey of FDA Adverse Event Reporting System data for the occurrence of SS in a larger database. We found 20 SS cases in people exposed to MDMA, all of which had also taken one or more substances with serotonergic properties in addition to MDMA, including amphetamines, stimulants, and opioids. There were no cases of SS associated with MDMA where MDMA was the sole reported compound taken.https://www.frontiersin.org/articles/10.3389/fpsyt.2021.824288/fullserotonin syndromeMDMA (3, 4- methylenedioxymethamphetamine)FAERS databasesurveillance systemcase reports [publication type] |
| spellingShingle | Tigran Makunts Tigran Makunts Lisa Jerome Ruben Abagyan Alberdina de Boer Reported Cases of Serotonin Syndrome in MDMA Users in FAERS Database Frontiers in Psychiatry serotonin syndrome MDMA (3, 4- methylenedioxymethamphetamine) FAERS database surveillance system case reports [publication type] |
| title | Reported Cases of Serotonin Syndrome in MDMA Users in FAERS Database |
| title_full | Reported Cases of Serotonin Syndrome in MDMA Users in FAERS Database |
| title_fullStr | Reported Cases of Serotonin Syndrome in MDMA Users in FAERS Database |
| title_full_unstemmed | Reported Cases of Serotonin Syndrome in MDMA Users in FAERS Database |
| title_short | Reported Cases of Serotonin Syndrome in MDMA Users in FAERS Database |
| title_sort | reported cases of serotonin syndrome in mdma users in faers database |
| topic | serotonin syndrome MDMA (3, 4- methylenedioxymethamphetamine) FAERS database surveillance system case reports [publication type] |
| url | https://www.frontiersin.org/articles/10.3389/fpsyt.2021.824288/full |
| work_keys_str_mv | AT tigranmakunts reportedcasesofserotoninsyndromeinmdmausersinfaersdatabase AT tigranmakunts reportedcasesofserotoninsyndromeinmdmausersinfaersdatabase AT lisajerome reportedcasesofserotoninsyndromeinmdmausersinfaersdatabase AT rubenabagyan reportedcasesofserotoninsyndromeinmdmausersinfaersdatabase AT alberdinadeboer reportedcasesofserotoninsyndromeinmdmausersinfaersdatabase |